<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><label>Table 2.</label><caption><title>List of parameters used in the model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>&#8195;#</th><th>Name</th><th>Description</th><th>Value</th><th>Reference</th></tr></thead><tbody><tr><td>&#8195;1</td><td><italic>V</italic></td><td>Set of villages</td><td>|<italic>V</italic>|&#160;=&#160;1000</td><td/></tr><tr><td>&#8195;2</td><td><italic>N</italic></td><td>Set of individuals across all villages</td><td>|<italic>N</italic>|&#160;=&#160;314,795</td><td>-</td></tr><tr><td>&#8195;3</td><td><italic>ml</italic></td><td>Proportion of males in the population</td><td>0.48</td><td>(<xref ref-type="bibr" rid="bib41">National Institute of Statistics, 2008</xref>)</td></tr><tr><td>&#8195;4</td><td><italic>maxage</italic></td><td>Maximum age</td><td>80 years</td><td>-</td></tr><tr><td>&#8195;5</td><td><italic>beta</italic></td><td>Biting rate</td><td>variable<sup>*</sup></td><td>-</td></tr><tr><td>&#8195;6</td><td><italic>previ</italic></td><td>Initial proportion of infectious people</td><td>variable<sup>*</sup></td><td>-</td></tr><tr><td>&#8195;7</td><td><italic>resit</italic></td><td>Initial proportion of artemisinin resistant infections</td><td>variable<sup>*</sup></td><td>-</td></tr><tr><td>&#8195;8</td><td><italic>netuse</italic></td><td>Proportion of individuals that own an insecticide treated bed net</td><td>0.5</td><td>-</td></tr><tr><td>&#8195;9</td><td><italic>itneffect</italic></td><td>proportional decrease of individual susceptibility/infectiousness related to ITN usage</td><td>0.2</td><td>-</td></tr><tr><td>&#8195;10</td><td><italic>ovstay</italic></td><td>Mean number of nights spent somewhere when undertaking short-term population movement</td><td>3</td><td>-</td></tr><tr><td>&#8195;11</td><td><italic>crit</italic></td><td>Critical distance below which overnight stays somewhere other than your home are made very unlikely</td><td>4 km</td><td>-</td></tr><tr><td>&#8195;12</td><td><italic>timecomp</italic></td><td>Mean time to complete ACT routine treatment</td><td>4 days</td><td>Best guess</td></tr><tr><td>&#8195;13</td><td><italic>fullcourse</italic></td><td>Proportion that receives treatment full course</td><td>0.8</td><td>(<xref ref-type="bibr" rid="bib74">Yeung et al., 2008</xref>)</td></tr><tr><td>&#8195;14</td><td><italic>covab</italic></td><td>Proportion of symptomatic cases that receive antimalarials</td><td>0.6</td><td>(<xref ref-type="bibr" rid="bib74">Yeung et al., 2008</xref>)</td></tr><tr><td>&#8195;15</td><td><italic>nomp</italic></td><td>Relative probability of receiving treatment in a non-malaria post village</td><td>0.1</td><td>Best guess</td></tr><tr><td>&#8195;16</td><td><italic>asymtreat</italic></td><td>Relative probability of receiving treatment without clinical symptom</td><td>10<sup>&#8722;4</sup></td><td>-</td></tr><tr><td>&#8195;17</td><td><italic>tauab</italic></td><td>Daily probability of receiving ACT in a village under MDA</td><td>1/1.5</td><td>-</td></tr><tr><td>&#8195;18</td><td><italic>gamma</italic></td><td>Mean liver stage duration</td><td>5 days</td><td>(<xref ref-type="bibr" rid="bib12">Collins and Jeffery, 1999</xref>; <xref ref-type="bibr" rid="bib22">Eyles and Young, 1951</xref>)</td></tr><tr><td>&#8195;19</td><td>sigma</td><td>Mean time to infectiousness after liver emergence</td><td>15 days</td><td>(<xref ref-type="bibr" rid="bib32">Jeffery and Eyles, 1955</xref>)</td></tr><tr><td>&#8195;20</td><td>mellow</td><td>Mean duration of symptoms</td><td>3 days</td><td>(<xref ref-type="bibr" rid="bib10">Church et al., 1997</xref>)</td></tr><tr><td>&#8195;21</td><td><italic>xa0</italic></td><td>Daily probability of going below the minimum effective artemisinin concentration</td><td>1/7</td><td>(<xref ref-type="bibr" rid="bib34">Karbwang et al., 1998</xref>)</td></tr><tr><td>&#8195;22</td><td><italic>xai</italic></td><td>Daily probability losing the DHA effect as part of ACT</td><td>1/3</td><td>(<xref ref-type="bibr" rid="bib51">Rijken et al., 2011</xref>;&#160;<xref ref-type="bibr" rid="bib63">Tarning et al., 2008</xref>)</td></tr><tr><td>&#8195;23</td><td><italic>xab</italic></td><td>Daily probability of going below the minimum effective piperaquine concentration</td><td>1/30</td><td>(<xref ref-type="bibr" rid="bib51">Rijken et al., 2011</xref>;&#160;<xref ref-type="bibr" rid="bib63">Tarning et al., 2008</xref>)</td></tr><tr><td>&#8195;24</td><td><italic>xpr</italic></td><td>Daily probability of going below the minimum effective primaquine concentration</td><td>1/2</td><td>(<xref ref-type="bibr" rid="bib7">Burgess and Bray, 1961</xref>)</td></tr><tr><td>&#8195;25</td><td><italic>delta</italic></td><td>Mean duration of a malaria untreated infection</td><td>160 days</td><td>(<xref ref-type="bibr" rid="bib22">Eyles and Young, 1951</xref>; <xref ref-type="bibr" rid="bib5">Babiker et al., 1998</xref>; <xref ref-type="bibr" rid="bib24">Franks et al., 2001</xref>)</td></tr><tr><td>&#8195;26</td><td><italic>imm_min</italic></td><td>Minimum clinical immunity period</td><td>40 days</td><td>Best guess</td></tr><tr><td>&#8195;27</td><td><italic>alpha</italic></td><td>Average permanence in each immunity level</td><td>60 days</td><td>-</td></tr><tr><td>&#8195;28</td><td><italic>phic</italic></td><td>Relative infectiousness of symptomatic infections compared to sub-patent ones</td><td>1</td><td>-</td></tr><tr><td>&#8195;29</td><td><italic>mdi</italic></td><td>Mosquito daily probability of dying while infectious</td><td>1/7</td><td>(<xref ref-type="bibr" rid="bib17">Dawes et al., 2009</xref>)</td></tr><tr><td>&#8195;30</td><td><italic>mdn</italic></td><td>Mosquito daily probability of dying while infected but not yet infectious</td><td>1/20</td><td>(<xref ref-type="bibr" rid="bib17">Dawes et al., 2009</xref>)</td></tr><tr><td>&#8195;31</td><td><italic>mgamma</italic></td><td>Mean extrinsic incubation period</td><td>14 days</td><td>(<xref ref-type="bibr" rid="bib58">Smith et al., 2014</xref>)</td></tr><tr><td>&#8195;32</td><td><italic>amp</italic></td><td>Amplitude of mosquito density seasonal variation</td><td>0.6</td><td>Best guess</td></tr><tr><td>&#8195;33</td><td><italic>process</italic></td><td>Days needed to administer a full ACT course in one village</td><td>4 days</td><td>Optimistic guess</td></tr><tr><td>&#8195;34</td><td><italic>rounds</italic></td><td>Number of drug rounds in an MDA campaign</td><td>3</td><td>Standard practice</td></tr><tr><td>&#8195;35</td><td><italic>btrounds</italic></td><td>Number of days between drug rounds in an MDA campaign</td><td>32</td><td>Standard practice</td></tr><tr><td>&#8195;36</td><td><italic>vcefficacy</italic></td><td>Vector control efficacy</td><td>variable<sup>*</sup></td><td>-</td></tr><tr><td>&#8195;37</td><td><inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing blood stage drug sensitive parasites with circulating dha</td><td>1/5</td><td>(<xref ref-type="bibr" rid="bib1">Adjuik et al., 2004</xref>;&#160;<xref ref-type="bibr" rid="bib50">Pukrittayakamee et al., 2004</xref>)</td></tr><tr><td>&#8195;38</td><td><inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing blood stage artemisinin resistant parasites with dha</td><td>0.27*<inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> <break/>(0.05)</td><td>(<xref ref-type="bibr" rid="bib18">Dondorp et al., 2009</xref>)</td></tr><tr><td>&#8195;39</td><td><inline-formula><mml:math id="inf5"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage drug sensitive parasites with circulating dha</td><td>1/3</td><td>(<xref ref-type="bibr" rid="bib1">Adjuik et al., 2004</xref>;&#160;<xref ref-type="bibr" rid="bib50">Pukrittayakamee et al., 2004</xref>)</td></tr><tr><td>&#8195;40</td><td><inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage artemisinin resistant parasites with dha</td><td>0.27*<inline-formula><mml:math id="inf7"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> <break/>(0.09)</td><td>(<xref ref-type="bibr" rid="bib18">Dondorp et al., 2009</xref>)</td></tr><tr><td>&#8195;41</td><td><inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing blood stage drug sensitive parasites with circulating dha- piperaquine</td><td>1/3</td><td>(<xref ref-type="bibr" rid="bib1">Adjuik et al., 2004</xref>; <xref ref-type="bibr" rid="bib50">Pukrittayakamee et al., 2004</xref>)</td></tr><tr><td>&#8195;42</td><td><inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing blood stage artemisinin resistant parasites with dha- piperaquine</td><td>0.27*<inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> + (1.0&#8211;0.27)*<inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> <break/>(0.33)</td><td>(<xref ref-type="bibr" rid="bib18">Dondorp et al., 2009</xref>)</td></tr><tr><td>&#8195;43</td><td><inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage <break/>drug sensitive parasites with circulating dha- piperaquine</td><td>1/3</td><td>(<xref ref-type="bibr" rid="bib8">Bustos et al., 2013</xref>)</td></tr><tr><td>&#8195;44</td><td><inline-formula><mml:math id="inf13"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage artemisinin resistant parasites with dha- piperaquine</td><td>0.27*<inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> + (1.0&#8211;0.27)*<inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> <break/>(0.126)</td><td>-</td></tr><tr><td>&#8195;45</td><td><inline-formula><mml:math id="inf16"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing blood stage drug sensitive parasites with circulating piperaquine</td><td>1/3</td><td>(<xref ref-type="bibr" rid="bib9">Chen et al., 1982</xref>)</td></tr><tr><td>&#8195;46</td><td><inline-formula><mml:math id="inf17"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing blood stage artemisinin resistant parasites with piperaquine</td><td>1/3</td><td>(<xref ref-type="bibr" rid="bib9">Chen et al., 1982</xref>)</td></tr><tr><td>&#8195;47</td><td><inline-formula><mml:math id="inf18"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage drug sensitive parasites with circulating piperaquine</td><td>1/20</td><td>(<xref ref-type="bibr" rid="bib40">Myint et al., 2007</xref>)</td></tr><tr><td>&#8195;48</td><td><inline-formula><mml:math id="inf19"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage artemisinin resistant parasites with piperaquine</td><td>1/20</td><td>(<xref ref-type="bibr" rid="bib40">Myint et al., 2007</xref>)</td></tr><tr><td>&#8195;49</td><td><inline-formula><mml:math id="inf20"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mn>0</mml:mn><mml:mo>&#8729;</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage drug sensitive parasites with primaquine</td><td>1/1.5</td><td>(<xref ref-type="bibr" rid="bib7">Burgess and Bray, 1961</xref>; <xref ref-type="bibr" rid="bib60">Smithuis et al., 2010</xref>)</td></tr><tr><td>&#8195;50</td><td><inline-formula><mml:math id="inf21"><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>&#8729;</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Daily probability of clearing infectious stage <break/>artemisinin resistant parasites with primaquine</td><td>1/1.5</td><td>-</td></tr><tr><td>&#8195;51</td><td><italic>k</italic></td><td>Steepness of susceptibility increase with age</td><td>0.14</td><td>(<xref ref-type="bibr" rid="bib2">Aguas et al., 2008</xref>)</td></tr><tr><td>&#8195;52</td><td><italic>r</italic></td><td>Amplitude of susceptibility increase with age</td><td>0.99</td><td>(<xref ref-type="bibr" rid="bib2">Aguas et al., 2008</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>the values are varied in different simulation settings. Their values are given in the description of each set of experiments and the set of possible values is given in <xref ref-type="table" rid="table1">Table 1</xref>.</p></fn></table-wrap-foot></table-wrap>